Literature DB >> 24055413

Histone deacetylase inhibitors in multiple myeloma.

Guy Pratt1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24055413     DOI： 10.1016/S1470-2045(13)70425-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses.

Authors:  J Ren; X Liao; M D Vieson; M Chen; R Scott; J Kazmierczak; X M Luo; C M Reilly
Journal:  Clin Exp Immunol       Date:  2017-10-16       Impact factor: 4.330

2.  In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Authors:  Ken Maes; Eva De Smedt; Alboukadel Kassambara; Dirk Hose; Anja Seckinger; Els Van Valckenborgh; Eline Menu; Bernard Klein; Karin Vanderkerken; Jérôme Moreaux; Elke De Bruyne
Journal:  Oncotarget       Date:  2015-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.